Objective: To determine whether treatment with recombinant human thrombomodulin (rhTM) increases survival among severe septic patients with sepsis-induced disseminated intravascular coagulation (DIC
Sepsis contributes to a major burden of disease in early life. Extensive characterization of interactions between host and bacteria in children is required to design novel preventive and therapeutic s
